Men with type 2 diabetes receiving GnRH agonists had a 26% higher risk of a 10% increase in predicted 5-year CVD risk score during the 11-year follow-up compared with men with type 2 diabetes without PCa; men with type 2 diabetes and PCa receiving GnRH agonists had a 52% higher risk compared with men with type 2 diabetes and PCa not receiving GnRH agonists. Here, GNRH1 is linked to type 2 diabetes mellitus.